Neuroleptic malignant syndrome associated with amoxapine and lithium in an older adult.
This report describes the presentation of neuroleptic malignant syndrome (NMS) in the primary care setting in an older adult with major depression with psychosis. This patient had been stable on a regimen of amoxapine, lithium carbonate, lorazepam, and benztropine. The patient had rigidity, altered sensorium, diaphoresis, autonomic instability, elevated WBC count and urine myoglobin, and creatine phosphokinase (CPK) reaching 1331 U/I. He was successfully treated with bromocriptine.
Gupta
S
S
Department of Psychiatry SUNY Health Science Center at Syracuse, New York, USA.
Racaniello
A A
AA
D000657:Amoxapine / Q000009:adverse effects* / Q000627:therapeutic use; D018687:Antidepressive Agents, Second-Generation / Q000009:adverse effects* / Q000627:therapeutic use; D018692:Antimanic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D003866:Depressive Disorder / Q000188:drug therapy; D006801:Humans; D018021:Lithium Chloride / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009459:Neuroleptic Malignant Syndrome / Q000209:etiology*; D011618:Psychotic Disorders / Q000188:drug therapy
D018687:Antidepressive Agents, Second-Generation; D018692:Antimanic Agents; D018021:Lithium Chloride; D000657:Amoxapine